Apollon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Apollon Wealth Management's VRTX Position: Q3 2026 in Review
Apollon Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q3 2026, selling an estimated $3.57M and leaving 56,933 shares worth $29.8M. The position accounts for 0.34% of the portfolio, ranked #56.
Apollon Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 21 quarters since. The position peaked at $31.7M in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Apollon Wealth Management held 56,933 shares of Vertex Pharmaceuticals worth $29.8M as of Q3 2026.
- Apollon Wealth Management sold 6,977 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.57M.
- Vertex Pharmaceuticals made up 0.34% of Apollon Wealth Management's portfolio in Q3 2026, its #56 holding.
- Apollon Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
- Apollon Wealth Management's Vertex Pharmaceuticals position peaked at $31.7M in Q2 2026.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.